523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis
| Autor: | Van Nieuwenhuysen, E., O'Malley, D., O'Cearbhaill, R.E., Moore, K.N., Hamilton, E.P., Yeku, O., Bouberhan, S., Hou, J.Y., Yoo, S-Y., Brouwer-Visser, J., Cheung, H.K., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Rowlands, T., Uldrick, T.S., Miller, E.A., Liu, J.F. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S784-S784 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|